A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC

Stopped early · Phase 2

Conditions studied: Non-Small Cell Lung Cancer, NSCLC, Adenocarcinoma, Heregulin

In brief

The purpose of this study is to determine whether the combination of MM-121 plus docetaxel is more effective than docetaxel alone in regards to PFS in patients with heregulin-positive NSCLC.

Key facts

Study ID

NCT02387216

Run by

Elevation Oncology

People needed

153

Starts

2015-02-01

Expected to finish

2019-01-02

Last updated by the study team

2021-10-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with a diagnosis of cytologically or histologically documented adenocarcinoma of the lung with either metastatic disease (stage IV), Stage IIIB or Stage IIIC disease not amenable to surgery with curative intent
• Not received more than 2 prior systemic therapies- one of which must have been a platinum based regimen- for primary or recurrent disease
• Tissue submitted for HRG-biomarker testing
• ECOG performance status (PS) of 0 or 1

You may not qualify if…

• Known ALK mutation
• Presence of exon 19 deletion or exon 21 (L858R) substitution of the EGFR gene
• Received >2 prior systemic anti-cancer drug regimen for locally advanced disease
• Prior treatment with an anti-ErbB3 antibody
• CTCAE grade 3 or higher peripheral neuropathy
• Symptomatic CNS metastases or CNS metastases requiring steroids
• Any other active malignancy requiring systemic therapy
• Clinically significant cardiac disease

Where it is running

• Study site — Tucson, Arizona, United States
• Study site — Los Angeles, California, United States
• Study site — Santa Rosa, California, United States
• Study site — Tampa, Florida, United States
• Study site — Chicago, Illinois, United States
• Study site — Lafayette, Indiana, United States
• Study site — Boston, Massachusetts, United States
• Study site — Boston, Massachusetts, United States
• Study site — Danvers, Massachusetts, United States
• Study site — New York, New York, United States
• Study site — The Bronx, New York, United States
• Study site — Philadelphia, Pennsylvania, United States
• Study site — Pittsburgh, Pennsylvania, United States
• Study site — Nashville, Tennessee, United States
• Study site — Nashville, Tennessee, United States
• Study site — Fairfax, Virginia, United States
• Study site — Seattle, Washington, United States
• Study site — Toronto, Ontario, Canada
• Centre Léon Bérard — Lyon, Auvergne-Rhône-Alpes, France
• CHI Creteil — Créteil, Paris, France
• Study site — München, Bavaria, Germany
• Study site — Bad Berka, Germany
• Study site — Berlin, Germany
• Study site — Frankfurt, Germany
• Study site — Oldenburg, Germany

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.